Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

10th annual World Medical Innovation Forum (WMIF) Monday, Sept. 23–Wednesday, Sept. 25 at the Encore Boston Harbor in Boston

Dr. Aviva Lev-Ari, PhD, RN, Founder

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

will be in attendance

covering this event in REAL TIME for PharmaceuticalIntelligence.com and WMIF organizers

#WMIF2024

@Pharma_BI

@AVIVA1950

CLAIMER: Live coverage in REAL TIME on X.com for 9/23/2024

• 8AM to 3:40PM
• at 3:40PM the handles

  @Pharma_BI

  @AVIVA1950

my two X.com accounts had exceeded tweeting volume capacity and were inactivated to verify if I am a person or a BOT. Account authentication reported SOmething went wrong, try later.

• 9/23/2024 contacted Customer Services at X.com for reactivated these two accounts

For Speaker’s quotes on 9/23/2024 from 4PM EST to end on the day

• see below on WordPress.com by Date, Time, Session Name and Speaker Name

For Speaker’s quotes on 9/24/2024 from 8AM to 5:30PM

• see below on WordPress.com by Date, Time, Session Name and Speaker Name

For Speaker’s quotes on 9/25/2024 from 8AM to 12:35PM

• see below on WordPress.com by Date, Time, Session Name and Speaker Name

UPDATE on reactivation of handles on X.com will be posted, here.

Usage of X.com will resume after Handle reactivation by X.com

UPDATED on 9/26/2024

Unmet Needs Panel

https://www.youtube.com/watch?v=e6hk7yavBzk

100+ Mass General Brigham Leading Experts Identify

Top Unmet Needs in Healthcare

Project from Harvard Medical School-affiliated clinicians and scientists in the Mass General Brigham healthcare system stimulates new consideration, urgency regarding

innovation in life sciences, healthcare

Top 10 List Announced at World Medical Innovation Forum

BOSTON, MA September 25, 2024 – Some of the most vexing challenges and transformational opportunities in healthcare are included in a new list, “Top Unmet Needs in Healthcare” released by leading experts at Mass General Brigham. Identified by more than 100 Harvard Medical School faculty at Mass General Brigham, the findings range from the need to expand and accelerate rare disease treatment, to the coming “gray tsunami” of aging patients and the implications for patient care, delivery, and technology. The project, revealed at the 10th annual World Medical Innovation Forum, is meant to stimulate new consideration and urgency regarding solving and advancing these issues for improved patient care.

Views from Leading Clinicians, Researchers, and Practitioners in Academic Medicine

The Top Unmet Needs emerge from structured one-on-one discussions with more than 100 Harvard faculty who practice medicine and conduct research at Mass General Brigham, the largest hospital system-based research enterprise in the U.S., with an annual research budget exceeding $2 billion, and five of the nation’s top hospitals according to US News & World Report.

Through one-on-one discussions with these key opinion leaders from diverse clinical and research fields, and subsequent analyses by internal teams of experts, Mass General Brigham has identified the following top 10 unmet clinical needs:

#1. Preparing for the ‘Gray Tsunami’

The need for better tools and therapies aimed at caring for geriatric populations and maintaining geriatric independence, with a particular focus on expanded hospital-at-home capabilities, and the need to better understand the pathways that lead to chronic and acute disease in geriatric patients to enable better and more proactive treatment.

#2. Defining and Maintaining Brain Health

The need for a model of brain health and neurological care that clearly defines not only what brain health is but also integrates our current understanding of the mechanisms and phases of neuroinflammatory and neurodegenerative diseases; enables better and earlier diagnoses and treatment; and propels the development of therapies that target these mechanisms and phases.

#3. A Paradigm Shift in Cancer Treatment

The need for a new framework for therapeutic development in cancer that is focused on improving curability as opposed to an exclusive focus on the development of drugs for metastatic disease. This

framework also requires effective tools for early-stage cancer detection across the board in all cancers, but especially in lung, ovarian, pancreatic, and GI cancers (esophagus, stomach and colon).

#4. Targeting Fibrosis, a Shared Culprit in Disease

The need for therapeutics that target fibrosis (tissue scarring), which is responsible for a significant percentage of deaths worldwide, representing diseases of the lung, liver, kidney, heart, and skin.

#5. New Approaches for Infectious Disease in a Changing World

The need for novel strategies for the rapid diagnoses, treatment, and even prevention of antibiotic-resistant infections, and the need for the next generation of globally deployable vaccines to enable pandemic preparedness.

#6. Striving for Equity in Healthcare

The need to radically rethink how, when, and where patients interact with healthcare services to optimize healthcare access and efficiency without diminishing its effectiveness, and to proactively meet the needs of currently underserved populations.

#7. Riding the Wave of Clinical Data

The need to expand the scope of available clinical data to include historically understudied populations (including women) and to model and implement a cohesive, dynamic data “stream,” which flows as patients do between the different phases of health and clinical care, enabling comparisons of patients to their previously healthy selves and the development of AI/ML approaches to harness these data to improve diagnosis, prognosis, and treatment.

#8. A Systems-Level View of Human Disease

The need to rethink how we understand and treat disease — not only from an organ-specific standpoint but from a whole-body, systems-level view — and to fully elucidate the roles that inflammation and immune pathways play in autoimmune and infectious diseases and their effects on chronic and acute diseases in diverse human systems, such as the cardiovascular/circulatory and nervous systems.

#9. A New Approach to Psychiatric Disease

The need for novel treatments for psychiatric disease, improved biomarkers and minimally invasive and ambulatory ways of measuring them, and more productive interactions with industry to advance new therapies to the clinic. This includes hybrid therapies (therapies that combine elements such as talk therapy, novel biomarkers, and pharmacological treatments) as well as new diagnostic and treatment modalities, such as psychedelic therapeutics and precision psychiatry.

#10. Charting a Course in Rare Disease Treatment

The need for viable treatments for the 7,000 identified rare diseases, especially the roughly 70% of such diseases that are genetic and the effects of which are first observed in early childhood.

The Unmet Needs list also include the following honorable mentions which rose to significant rankings in the analysis:

• Driving Innovation in Chronic Disease: Improved Diagnosis, Treatment, and Prevention
• A New Era of Obesity Medicine
• A New Generation of Pain Treatments
• Unlocking Novel Treatments for the Skin

Overarching Themes

Addressing unmet clinical needs involves solving a number of common challenges, including commercialization hurdles, regulatory considerations, and funding. The Mass General Brigham project identified overarching themes to help address these challenges and support innovation across multiple sectors. These include:

• Taking a systems view of human disease and the practice of system-medicine
• Developing a global view of infectious disease, including antimicrobial resistance
• An expansion in high-quality, real-world data that closes gaps in current data (particularly for women and other underserved populations) and ensures that data sets are sufficiently enabling for AI/ML
• Improving health and healthcare across key populations, including geriatrics and rare genetic disease
• Addressing major diseases of the brain, including both neurodegenerative and neuropsychiatric conditions; these include Alzheimer’s disease, Parkinson’s disease, ALS, as well as psychiatric and mental health disorders
• Opening an era of precision medicine across disease areas that includes early diagnosis, treating staged disease, and biomarker discovery and utilization

Panel co-chairs José Florez, Physician-in-Chief and Co-Chair of the MGB Department of Medicine and the Jackson Professor of Clinical Medicine at Harvard Medical School, and Bruce Levy, Physician-In-Chief and Co-Chair of the MGB Department of Medicine and the Parker B. Francis Professor of Medicine at Harvard Medical School, noted how the observations of a broad and representative set of faculty help illuminate the innovation landscape ahead.

“As a leader in patient care and healthcare innovation, our goal is to build on the legacy of research and discovery that has shaped the hospitals of the Mass General Brigham healthcare system for more than a hundred years, and continue to bring breakthroughs forward that can help solve pressing needs,” said Dr. Florez.

Dr. Levy added that “This is a roadmap for the future that can inform discussions happening throughout the healthcare and investment ecosystem regarding the future of medicine.”

More than 2000 decision-makers from healthcare, industry, finance and government attended the World Medical Innovation Forum this week in Boston. A premier global event, the Forum highlights leading innovations in medicine and transformative advancements in patient care.

###

About Mass General Brigham

Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

Contact: Tracy Doyle Mass General Brigham Innovation

(262) 227-5514

Tdoyle5@mgb.org

SOURCE

From: “Doyle, Tracy” <tdoyle5@mgb.org>
Date: Thursday, September 26, 2024 at 10:19 AM
Cc: “Card, Matthew” <matthew.card@bofa.com>
Subject: Unmet Needs in Healthcare — Press Release and link to panel

@@@@@@@

Invitation as MEDIA

From: “Doyle, Tracy” <tdoyle5@mgb.org>
Date: Wednesday, August 14, 2024 at 4:04 PM
Cc: “Doyle, Tracy” <tdoyle5@mgb.org>, “Card, Matthew” <matthew.card@bofa.com>
Subject: Media Invite: World Medical Innovation Forum, Sept. 23-25, Boston — Hundreds of clinical experts, industry, investment leaders

 

Media Invite: World Medical Innovation Forum: Monday, Sept. 23—Wednesday, Sept. 25, Boston

At the intersection of innovation and investment in healthcare

Join Us!

Register Now: WMIF24 Media Registration

Mass General Brigham, one of the nation’s leading academic medical centers, is pleased to invite reporters to the 10^th annual World Medical Innovation Forum (WMIF) Monday, Sept. 23–Wednesday, Sept. 25 at the Encore Boston Harbor in Boston. The event features expert discussions of scientific and investment trends for some of the hottest areas in healthcare, including

• GLP-1s,
• the cancer care revolution,
• generative AI-enabled care paths,
• xenotransplant,
• community health,
• hospital at home, and
• therapeutic psychedelics, among many others.

 

The agenda includes nearly 175 executive speakers from healthcare, pharma, venture, start-ups, and the front lines of care, including many of Mass General Brigham’s Harvard Medical School-affiliated researchers and clinicians who this year will host 20+ focused sessions. Bank of America, presenting sponsor of the Forum, will provide additional expert insights on the investment landscape associated with healthcare innovation.

 

Forum highlights include:

 

1:1 and panel interviews with leading CEOs and government officials including:

• Stéphane Bancel, CEO, Moderna
• Albert Bourla, PhD, CEO, Pfizer
• Marc Casper, CEO, Thermo Fisher
• Deepak Chopra, MD, Founder, The Chopra Foundation
• Scott Gottlieb, MD, PhD, Former Commissioner, FDA (2017-2019)
• Maura Healey, Governor, Commonwealth of Massachusetts
• David Hyman, MD, CMO, Eli Lilly

• Haim Israel, Head of Global Thematic Investing Research, BofA Global Research
• Reshma Kewalramani, MD, CEO, Vertex
• Anne Klibanski, MD, President and CEO, Mass General Brigham
• Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
• Tadaaki Taniguchi, MD, PhD, Chief Medical Officer, Astellas Pharma
• Christophe Weber, CEO, Takeda
• Renee Wegrzyn, PhD, Director, ARPA-H

 

Expert panels including:

• Oncology’s New Paradigm
• Gene Therapies for Rare Diseases
• Future of Metabolic Therapies
• Digital Transformation
• Biologic Revolution in Radiotherapies
• Cell Therapies for Autoimmune Diseases
• Hospital Venture Funds

 

Leading biotech and venture speakers from companies including:

• Abata Therapeutics
• Atlas Venture
• Be Biopharma
• Everly Health
• Flagship Pioneering
• Fractyl Health
• MindMed
• Mirador Therapeutics
• Regor Therapeutics
• RH Capital
• Transcend Therapeutics

Exclusive programming:  

• First Look – 15 rapid-fire presentations on the latest research from leading Mass General Brigham scientists
• Un-Met Clinical Needs – 100+ key opinion leaders in healthcare weigh in on the top un-met clinical needs in medicine today
• Emerging Tech Zone – Hands-on exploration of some of the latest digital and AI-based healthcare technologies

 

Our program keeps growing — explore the current Forum agenda and list of speakers.

FORUM AGENDA

SOURCE

https://2024.worldmedicalinnovation.org/agenda/

Monday, September 23, 2024

• • 7:00 AM – 8:30 AM

    Picasso Foyer

    Continental Breakfast

  • 7:00 AM – 5:00 PM

    Rotunda

    Registration

  • 8:00 AM – 10:00 AM

    Picasso Ballroom

    First Look

    First Look: 14 rapid fire presentations

    Moderators

    Giles Boland, MD

    President, Brigham and Women’s Hospital and Brigham and Women’s Physicians Organization;

    Philip H. Cook Distinguished Professor of Radiology, Harvard Medical School

    Marcela del Carmen, MD

    President, Massachusetts General Hospital and Massachusetts General Physicians Organization (MGPO);

    Executive Vice President, Mass General Brigham;

    Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

    Presenters

    Natalie Artzi, PhD

    Associate Professor of Medicine, Brigham and Women’s Hospital & Harvard Medical School

    Yolonda Colson, MD, PhD

    Chief, Division of Thoracic Surgery, Massachusetts General Hospital;

    Hermes C. Grillo Professor of Surgery, Harvard Medical School

    Nobuhiko Hata, PhD

    Director, Surgical Navigation and Robotics Laboratory, Brigham and Women’s Hospital;

    Professor of Radiology, Harvard Medical School

    John Hanna, MD, PhD

    Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

    Leigh Hochberg, MD, PhD

    Director of Neurotechnology and Neurorecovery, Massachusetts General Hospital;

    Senior Lecturer on Neurology, Harvard Medical School

    Daphne Holt, MD, PhD

    Director of the Resilience and Prevention Program, Massachusetts General Hospital;

    Associate Professor of Psychiatry, Harvard Medical School

    Ole Isacson, MD-PhD

    Founding Director, Neuroregeneration Research Institute, McLean Hospital;

    Professor of Neurology and Neuroscience, Harvard Medical School

    Farouc Jaffer, MD, PhD

    Director, Coronary Intervention, Massachusetts General Hospital;

    Associate Professor of Medicine, Harvard Medical School

    Albert Kim, MD

    Assistant Physician, Mass General Cancer Center;

    Assistant Professor, Harvard Medical School

    Vesela Kovacheva, MD, PhD

    Director of Translational and Clinical Research, Mass General Brigham;

    Assistant Professor of Anesthesia, Harvard Medical School

    Mark Poznansky, MD, PhD

    Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital;

    Steve and Deborah Gorlin MGH Research Scholar;

    Professor of Medicine, Harvard Medical School

    Daniel Solomon, MD

    Matthew H. Liang Distinguished Chair in Arthritis and Population Health, Brigham and Women’s Hospital;

    Professor of Medicine, Harvard Medical School

    Scott Solomon, MD

    Director, Clinical Trials Outcomes Center;

    Edward D. Frohlich Distinguished Chair in Cardiovascular Pathophysiology, Brigham and Women’s Hospital;

    Professor of Medicine, Harvard Medical School

    Guillermo Tearney, MD, PhD

    Principal Investigator, Wellman Center for Photomedicine, Massachusetts General Hospital;

    Remondi Family Endowed MGH Research Institute Chair;

    Professor of Pathology, Harvard Medical School

    Raul Uppot, MD

    Interventional Radiologist, Massachusetts General Hospital;

    Associate Professor, Harvard Medical School

    David Walt, PhD

    Professor of Pathology, Brigham and Women’s Hospital;

    Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School

  • 10:00 AM – 10:20 AM

    Morning Break

  • 10:20 AM – 10:30 AM

    Initial Welcome Remarks

  • 10:30 AM – 10:55 AM

    Fireside

    Fireside Chat

    Moderator

    Keith Flaherty, MD

    Director of Clinical Research, Mass General Cancer Center;

    Professor of Medicine, Harvard Medical School

    Panelist

    Albert Bourla, PhD

    Chairman & CEO, Pfizer

  • 11:00 AM – 11:45 AM

    Medicine’s Hottest Topics – Block I of IV

Concurrent Events

• 11:00 AM – 11:45 AM

  Oncology’s New Paradigm

  Moderators

  Keith Flaherty, MD

  Director of Clinical Research, Mass General Cancer Center;

  Professor of Medicine, Harvard Medical School

  Jason Zemansky, PhD

  SMid-Cap Biotech Analyst, BofA Global Research

  Panelists

  Jonathan Carlson, MD, PhD

  Director of Chemistry, Center for Systems Biology, Massachusetts General Hospital;

  Assistant Professor of Medicine, Harvard Medical School

  Gad Getz, PhD

  Director of Bioinformatics, Krantz Center for Cancer Research and Department of Pathology;

  Paul C. Zamecnik Chair in Cancer Research, Mass General Cancer Center;

  Professor of Pathology, Harvard Medical School

  Russell Jenkins, MD, PhD

  Krantz Family Center for Cancer Research, Massachusetts General Hospital;

  Mass General Cancer Center, Center for Melanoma;

  Assistant Professor of Medicine, Harvard Medical School

  Gregory Simon

  President, Simonovation

  Shannon Stott, PhD

  Associate Investigator, Krantz Family Center for Cancer Research and Mass General Cancer Center;

  d’Arbeloff Research Scholar, Massachusetts General Hospital;

  Associate Investigator, Krantz Family Center for Cancer Research Harvard Medical School

• 11:00 AM – 11:45 AM

  GLP-1s: How Far Will They Go?

  Moderators

  Tazeen Ahmad

  SMid-Cap Biotech Analyst, BofA Global Research

  Fatima Cody Stanford, MD

  Obesity Medicine Physician Scientist, Massachusetts General Hospital;

  Associate Professor of Medicine and Pediatrics, Harvard Medical School

  Panelists

  Caroline Apovian, MD

  Co-Director, Center for Weight Management and Wellness, Brigham and Women’s Hospital;

  Professor of Medicine, Harvard Medical School

  Vanita Aroda, MD

  Director, Diabetes Clinical Research, Brigham and Women’s Hospital;

  Associate Professor, Harvard Medical School

  Paul LaViolette

  Managing Partner & COO, SV Health Investors

• 11:00 AM – 11:45 AM

  Generative AI: Breakthrough Research and Limitations

  Moderators

  Adam Landman, MD

  Chief Information Officer & SVP, Digital, Mass General Brigham;

  Associate Professor of Emergency Medicine, Harvard Medical School

  Alec Stranahan, PhD

  SMid-Cap Biotech Analyst, BofA Global Research

  Panelists

  Katherine Andriole, PhD

  Director of Academic Research and Education, Mass General Brigham Data Science Office;

  Associate Professor, Harvard Medical School

  David Blumenthal, MD

  Professor of Practice of Public Health and Health Policy, Harvard TH Chan School of Public Health;

  Research Fellow, Harvard Kennedy School of Government;

  Samuel O. Thier Professor of Medicine, Emeritus, Harvard Medical School

  Faisal Mahmood, PhD

  Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

  William Morris, MD

  Chief Medical Information Officer, Google Cloud

• 11:00 AM – 11:45 AM

  Gene and Cell Therapy’s Unlimited Potential

  Moderators

  Roger Hajjar, MD

  Director, Gene & Cell Therapy Institute, Mass General Brigham

  Charlie Yang, PhD

  Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

  Nathan Yozwiak, PhD

  Head of Research, Gene and Cell Therapy Institute, Mass General Brigham

  Panelists

  Samarth Kulkarni, PhD

  CEO, CRISPR Therapeutics

  Peter Marks, MD, PhD

  Director, Center for Biologics Evaluation and Research, FDA

  Marcela Maus, MD, PhD

  Director of Cellular Therapy and Paula O’Keeffe Chair in Cancer Research, Krantz Family Center for Cancer Research and Mass General Cancer Center;

  Associate Director, Gene and Cell Therapy Institute, Mass General Brigham;

  Associate Professor, Harvard Medical School

  Joanne Smith-Farrell, PhD

  CEO & Director, Be Biopharma

• 11:00 AM – 11:45 AM

  Xenotransplant: Game Changing Organ Replacement

  Moderators

  Jason Gerberry

  Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

  Joren Madsen, MD, PhD

  Director, MGH Transplant Center;

  Paul S. Russell/Warner-Lambert Professor of Surgery, Harvard Medical School

  Panelists

  Tatsuo Kawai, MD, PhD

  Director of the Legorreta Center for Clinical Transplantation Tolerance,

  A.Benedict Cosimi Chair in Transplant Surgery, Massachusetts General Hospital;

  Professor of Surgery, Harvard Medical School

  Richard Pierson III, MD

  Scientific Director, Center for Transplantation Sciences, Massachusetts General Hospital;

  Professor of Surgery, Harvard Medical School

  Leonardo Riella, MD, PhD

  Medical Director of Kidney Transplantation, Massachusetts General Hospital;

  Harold and Ellen Danser Endowed Chair in Transplantation, Harvard Medical School

• • 11:45 AM – 12:00 PM

    Break

  • 12:00 PM – 12:45 PM

    Lunch and Medicine’s Hottest Topics – Block II of IV

Concurrent Events

• 12:00 PM – 12:45 PM

  Future of Cancer Care

  Moderator

  Alec Stranahan, PhD

  SMid-Cap Biotech Analyst, BofA Global Research

  Panelists

  Gerard Doherty, MD

  Surgeon-in-Chief, Mass General Brigham Cancer;

  Surgeon-in-Chief, Brigham and Women’s Hospital;

  Moseley Professor of Surgery, Harvard Medical School

  Daphne Haas-Kogan, MD

  Chief, Enterprise Radiation Oncology, Mass General Brigham;

  Professor, Harvard Medical School

  Benjamin Kann, MD

  Assistant Professor, Brigham and Women’s Hospital & Harvard Medical School

  David Ryan, MD

  Physician-in-Chief, Mass General Brigham Cancer;

  Professor of Medicine, Harvard Medical School

• 12:00 PM – 12:45 PM

  Generative AI Enabled Care Paths

  Moderators

  Adam Ron

  Health Care Facilities and Managed Care Analyst, BofA Global Research

  Marc Succi, MD

  Executive Director, Mass General Brigham MESH Incubator;

  Associate Chair of Innovation & Commercialization, Mass General Brigham Radiology;

  Assistant Professor, Harvard Medical School

  Panelists

  Christopher Longhurst, MD

  Chief Medical & Digital Officer, UC San Diego Health

  Rebecca Mishuris, MD

  Chief Medical Information Officer, Mass General Brigham;

  Member of the Faculty, Harvard Medical School

  Shiv Rao, MD

  CEO & Founder, Abridge

  Alkesh Shah

  Head of US Equity Software Research, BofA Global Research

• 12:00 PM – 12:45 PM

  Transforming Care in a Resource Limited Era

  Moderator

  Niyum Gandhi

  CFO & Treasurer, Mass General Brigham

  Panelists

  Fritz François, MD

  Executive Vice President and Vice Dean, Chief of Hospital Operations, NYU Langone Health

  Susan Huang, MD

  EVP, Chief Executive, Providence Clinical Network, Providence Southern CA

  Ron Walls, MD

  Chief Operating Officer, Mass General Brigham;

  Neskey Family Professor of Emergency Medicine, Harvard Medical School

• 12:00 PM – 12:45 PM

  Cardiovascular Pipeline Renewal

  Moderators

  Jason Gerberry

  Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

  Calum MacRae, MD, PhD

  Vice Chair for Scientific Innovation, Department of Medicine, Brigham and Women’s Hospital;

  Professor of Medicine, Harvard Medical School

  Panelists

  Lotte Bjerre Knudsen, DMSc

  Chief Scientific Advisor, Novo Nordisk

  David Grayzel, MD

  Partner, Atlas Venture

  Christoph Westphal, MD, PhD

  General Partner, Longwood Fund

  Deborah Wexler, MD

  Chief, Diabetes Unit, Massachusetts General Hospital;

  Associate Professor of Medicine, Harvard Medical School

• 12:45 PM – 1:00 PM

  Break and Transition to Plenary Session

• 1:00 PM – 1:20 PM

  Picasso Ballroom

  Opening Remarks

  Introducer

  Miceal Chamberlain

  President of Massachusetts, Bank of America

  Opening Remarks

  Maura Healey

  Governor of the Commonwealth of Massachusetts

• 1:20 PM – 2:00 PM

  Picasso Ballroom

  Healthcare Innovation and Regional Competitiveness

  Panelists

  John Fish

  Chairman & CEO, Suffolk

  Reshma Kewalramani, MD

  CEO & President, Vertex Pharmaceuticals

  Jonathan Kraft

  President, The Kraft Group;

  Board Chair, Massachusetts General Hospital

• 2:05 PM – 2:30 PM

  Picasso Ballroom

  Fireside

  Fireside Chat

  Moderators

  Tazeen Ahmad

  SMid-Cap Biotech Analyst, BofA Global Research

  Roger Hajjar, MD

  Director, Gene & Cell Therapy Institute, Mass General Brigham

  Panelist

  Reshma Kewalramani, MD

  CEO & President, Vertex Pharmaceuticals

• 2:35 PM – 3:10 PM

  Picasso Ballroom

  Delivering Care: New Tools, Evolving Challenges, Bold Aspirations

  Moderator

  Andrew Bressler

  Washington Healthcare Policy Analyst, BofA Global Research

  Panelists

  Rod Hochman, MD

  President & CEO, Providence

  Anne Klibanski, MD

  President & CEO, Mass General Brigham;

  Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

  Kevin Mahoney

  CEO, University of Pennsylvania Health System

• 3:10 PM – 3:35 PM

  Picasso Ballroom

  Fireside

  Fireside Chat

  Moderators

  Caroline Sokol, MD, PhD

  Assistant Physician, Massachusetts General Hospital;

  Assistant Professor, Harvard Medical School

  Charlie Yang, PhD

  Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

  Panelist

  Mark McKenna

  Chairman & CEO, Mirador Therapeutics

3:40 PM – 4:05 PM

Picasso Ballroom

RECORDING OF SPEAKERS’ QUOTES ON WordPress.com

 

STARTS HERE

Fireside

Fireside Chat

Moderators

Jason Gerberry

Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

Allan Goldstein, MD

Chief of Pediatric Surgery, Massachusetts General Hospital;

Surgeon-in-Chief, Mass General for Children;

Marshall K. Bartlett Professor of Surgery, Harvard Medical School

Panelist

Christophe Weber, President & CEO, Takeda

• pipeline is very diverse at the R&D center in Boston

Phase III:

• TAK-279 Psorisis
• Neurocrine’s Takeda-Partnered Drug Candidate Aces Phase II Depression Study

The Markets for Takeda

• US market is 40% of revenue, It is a difficult market but still the most important for Phama in the World
• Japan is 8%
• Growth by acquisitions and internal development like above, two Phase III drugs

Price control and policies:

• negotiation
• price war create tension

Team:

Public company traded in NYSE

• Management team has 10 nationalities – Global company
• AI is adopted as a digital companion

Recruiting Patients for Clinical Trial:

• Very difficult

M&A

• After acquisition of Shire – not many other opportunities are left

4:05 PM – 4:40 PM

Picasso Ballroom

The Innovation Gap: A Review of the Future of Viral Vector Manufacturing and the Delivery of Genetic Medicines

Moderators

Elizabeth Henske, MD, Director, Center for LAM Research and Clinical Care, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Panelists

Peter Anastasiou, CEO, Capsida Biotherapeutics

• Capsid technology for Liver disease, Parkinson’s
• AV and CNS crossing BBB
• One capsid for one disease
• manufacture caspids
• Challenges:  manufacturable after screening
• IV delivery – brain disorder, blood flow would bring therapeutics to all brain tissue consistently vs localized
• Partnership with Eli Lilly and with Crisper technologies with Abbvie

Steve Favaloro, Chairman & CEO, Genezen

• 200 persons Team manufacture
• Partnerships: synthetic plasma

Alexandria Forbes, PhD, CEO, MeiraGTx

• Optimize promoters, control transcription expression by injection or by pill, control translation
• improving potency of gene therapies capsule technology
• cost hundred of $ not thousand of $
• ALL manufacturing in house
• 9 years of data can help to narrow down the parameters
• time frame is shortened
• company established 9 years ago
• apply DNA expression – invented a technology
• splicing control mRNA
• control cell lines
• give an injection or a pill and control antibodies, glucagon
• control dosing for efficatious therapeutics
• Potency
• Ribozon is a delivery system
• Partnership with J&J –

Fraser Wright, PhD, Chief Gene Therapy Officer, Kriya Therapeutics

• manufacturing – changing in capsule design
• manufacture viruses
• cost of manufacturing – efficiency matters a lot
• delivery of the gene in the tissue
• Partnerships: basic vs applied Quality from research to manufacturing

4:45 PM – 5:20 PM

Picasso Ballroom

A Deep Dive on Genetic Modalities for Rare Disease: Genetic Medicines Are Here

Moderator

Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Global Research

• Treat once or repeat therapy?

Patricia Musolino, MD, PhD, MGH

 

Panelists

Faraz Ali, Tenaya Therpeutics

• genetic therapy for a genetic mutation – NOVEL approach
• 400 mutation related to cardiomyopathy
• 2018 – gene therapy was an innovation
• genetic medicine Cardiology introducing opportunities wiht validation that did not exist
• find novel targets Partnerships are a must to have
• Viral therapies vs gene therapy

Lucas Harrington, PhD, Co-Founder & CSO, Mammoth Biosciences

• How to turm Genome 2012 to therapy?
• targeting: Taking risk Patient interaction with treatment
• variation between Rare diseases some are very small some are not small – incentive to investors
• The field will grow fast

Raju Prasad, PhD, Chief Financial Officer, CRISPR Therapeutics

• various indications
• FDA Approval
• Gene editing technology for rare diseases
• LPA for RNA therapy
• incentive to investors
• Important for investor to understand the siize of the market, CRISPR can be a technology for a large market size
• Sickle cell disease – market is large and therapy can be made affordable

 

Sandi See Tai, MD, Chief Development Officer, Lexeo Therapeutics

• cardiomyopathy
• protective gene
• Early genetic testing
• Educating patients

5:20 PM – 6:30 PM

Picasso Terrace and Harborside Lawns 1 & 2

Opening Reception

Tuesday, September 24, 2024

• • 7:00 AM – 5:00 PM

    Rotunda

    Registration

8:00 AM – 8:55 AM

Picasso Ballroom

The Transforming World

Introducer

Liz Everett Krisberg, Head of Bank of America Institute

• Record attendance this year
• Introduction to Haim

Panelist

Haim Israel

Head of Global Thematic Investing Research, BofA Global Research

• Concept of the Future and for the Future: Short-term and long-term
• Humanity achievements in Ten Year: Data, Processing power and BRAIN – Long-term becomes Short-term – Last 10 years: 2012, 2014 solar system, 2015 medicine, 2019 blackhole, 2023 core of sun – star was created hotter than core sun
• 2022, 2024 – galaxy picture of the universe
• Volume of data created every month in terrabyts every 18 month data is duplicating itself.
• Olny 1% is used – imagine 2% or 3%
• Processing power since Apollo 11 [one trillion] – getting cheaper – cost for calculation went down 16,000 fold since 1995
• AMMOUNT of DATA goes up and Cost of COMPUTATION goes down – price per giga byte
• Projections for the next 100 years
• Negative for people and Negative for Companies who are concerned with quarterly financial data
• Companies: Walmart, Alphabet, Home Depot – DATA larger that COuntries
• Living in defining moment: started by iPhone revolution and 2023 by AI revolution – 6x outpaced Moore’s Law by GPT by 3000x
• 18 months into AI revolution – GPT in use
• The next 10 years:

1. Aging population
2. 2024 – birth rate low in US, Japan, CHina, S. Korea – Pension system will decline in size
3. 2.2 millions new material were created by DeepMind at Alphabet by simulation of AI on molecule
4. Microsoft in 80 hours identified 18 materials winners for Batteries using AI from 32 million material candidates
5. AI- weather calculations in minutes 1,000x faster, cheaper and more accurate
6. 2025 – GPT-6 AI surpass Human Brain
7. China is a big player in AI
8. Cyber CRIME is the 3rd largest economy in the World. Hackers are using ChatGPT to create fake pictures leading to ZERO privacy

• PRIVACY: Deepfakes up 62x, social media
• 2024 – Global Grid – needs much more energy because AI consumes so much energy
• Metals shortages: Nickel, Copper,
• Scarcity of water for 2/3 of the planet
• data centers consume water more than Japan
• 2025 – Genomics Data sequencing bigger that X.com or Youtube
• 2027 – Peak oil demand: needed to be scalable, cheaper 25%
• 2028 – 5G networks reaches full capacity, 6G will be needed
• 2029 – 25x more satellites in Orbit than today
• 2029 – Personalized AI medicines and treatments will manipulate death and revive LONGEVITY – AI will generate drugs and all treatments
• 2030 – Generative AI:  re-skill 1 Billion people
• 2035 – Fusion energy, known technology since the atomic bomb, how to keep it stable in plasma state of material – not yet achieved, it is clean, cheap: to Power the World – equivalent of 11 barrels of oil
• Large cities: Cable diameter 17cm wide to power a large city
• AI will change scarcity into abundance
• 2037 – Artifitial SUPER Intelligence – AI to outsmart Life
• Quantum computer – Consortium of NASA and other governmental agencies and Google on quantum computer design
• 2024 the most interesting year in human history

 

• • 9:00 AM – 9:45 AM

    Medicine’s Hottest Topics – Block III of IV

Concurrent Events

• 9:00 AM – 9:45 AM

  Current and Future States of Immunology

  Moderators

  Caroline Sokol, MD, PhD, Assistant Physician, Massachusetts General Hospital;, Assistant Professor, Harvard Medical School

  Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

  Panelists

  Dong Feng Chen, MD, PhD, Associate Scientist, Massachusetts Eye and Ear;, Associate Professor, Harvard Medical School

  Steven Grinspoon, MD, Chief, Metabolism Unit, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

  Alexandra-Chloé Villani, PhD, Investigator, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

• 9:00 AM – 9:45 AM

  Therapeutic Psychedelics – Opportunities and Impact

  Moderators

  Maurizio Fava, MD

  Chair, Department of Psychiatry, Massachusetts General Hospital;

  Slater Family Professor of Psychiatry, Harvard Medical School

  Jason Gerberry

  Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

  Kerry Ressler, MD, PhD

  Chief Scientific Officer, McLean Hospital;

  Professor of Psychiatry, Harvard Medical School

  Panelists

  Cristina Cusin, MD

  Director, MGH Ketamine Clinic and Psychiatrist, Depression Clinical and Research Program, Massachusetts General Hospital;

  Associate Professor in Psychiatry, Harvard Medical School

  Daniel Karlin, MD

  Chief Medical Officer, MindMed

  John Krystal, MD

  Chair, Department of Psychiatry, Yale School of Medicine

  Jennifer Warner-Schmidt, PhD

  Vice President, Scientific Affairs, Transcend Therapeutics

• 9:00 AM – 9:45 AM

  Innovations Advancing Community Health Equity

  Moderators

  Allen Lutz

  Health Care Services Analyst, BofA Global Research

  Elsie Taveras, MD

  Chief Community Health & Health Equity Officer, Mass General Brigham;

  Conrad Taff Endowed Chair and Professor of Pediatrics, Harvard Medical School

  Panelists

  Rebecca Mishuris, MD

  Chief Medical Information Officer, Mass General Brigham;

  Member of the Faculty, Harvard Medical School

  Claire-Cecile Pierre, MD

  Vice President, Community Health Programs, Mass General Brigham;

  Instructor in Medicine, Harvard Medical School

  Jorge Rodriguez, MD

  Clinician-investigator, Brigham and Women’s Hospital;

  Assistant Professor, Harvard Medical School

  Prabhjot Singh, MD, PhD

  Senior Advisor, Strategic Initiatives Peterson Health Technology Institute

• 9:00 AM – 9:45 AM

  Earliest Detection

  Moderators

  James Brink, MD

  Enterprise Chief, Radiology, Mass General Brigham;

  Juan M. Taveras Professor of Radiology, Harvard Medical School

  David Louis, MD

  Enterprise Chief, Pathology, Mass General Brigham

  Benjamin Castleman Professor of Pathology, Harvard Medical School

  Jason Zemansky, PhD

  SMid-Cap Biotech Analyst, BofA Global Research

  Panelists

  Jasmeer Chhatwal, MD, PhD

  Associate Neurologist, Massachusetts General Hospital;

  Associate Professor of Neurology, Harvard Medical School

  Pradeep Natarajan, MD

  Director of Preventive Cardiology, Paul & Phyllis Fireman Endowed Chair in Vascular Medicine, Massachusetts General Hospital;

  Associate Professor of Medicine, Harvard Medical School

  Yakeel Quiroz, PhD

  Director, Familial Dementia Neuroimaging Lab and Director, Multicultural Alzheimer’s Prevention Program, Massachusetts General Hospital;

  Paul B. and Sandra M. Edgerley MGH Research Scholar;

  Associate Professor, Harvard Medical School

  Heidi Rehm, PhD

  Chief Genomics Officer, Massachusetts General Hospital;

  Professor of Pathology, Harvard Medical School

• 9:00 AM – 9:45 AM

  Women’s Health Technology Revolution

  Moderators

  Tazeen Ahmad

  SMid-Cap Biotech Analyst, BofA Global Research

  Hadine Joffe, MD

  Executive Director of the Connors Center for Women’s Health and Gender Biology;

  Interim Chair, Department of Psychiatry, Brigham and Women’s Hospital;

  Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health, Harvard Medical School

  Panelists

  Keith Isaacson, MD

  Director of Minimally Invasive Gynecologic Surgery and Infertility, Newton Wellesley Hospital;

  Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

  Nawal Nour, MD

  Chair, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital;

  Associate Professor, Kate Macy Ladd Professorship, Harvard Medical School

  Kaveeta Vasisht, MD, PharmD

  Associate Commissioner, Women’s Health, U.S. Food and Drug Administration

  Alice Zheng, MD

  Principal, RH Capital

9:50 AM – 10:15 AM

Picasso Ballroom

Fireside

Fireside Chat

Moderator

David Brown, MD, President, Academic Medical Centers, Mass General Brigham; Mass General Trustees Professor of Emergency Medicine, Harvard Medical School

• Hoe do you balance Private medicine with Public not for profit HealthCare
• Healthcare delivery system can achieve that much in Human health
• Resources for Equity: housing and services: Capacity and COst
• Evolution of care close to home catalyst of the Pandemic – How government think about the right patient for the right care level
• MGB 40-60 In-patients at Home – Largest Program in the State  – product needs to scale across all population though some do not have food security at home

Panelist

Kate Walsh, Secretary of Health and Human Services, State of Massachusetts

• Stuart Bankrupcy – pstioents and providers involvement – structure challenges
• Race and ethnicity – disparities, access and equity
• Identify the challenge for Race and ethnicity
• Focus to identify resources
• Medicare & Medicaid – Human needs equity involve housing, food and home care – Public and Private sector cooperation
• Pay for Performance
• MA vs NYC – resources for welcoming new populations to the State of MA
• Help finding Housing vs Shelter people
• MA is the only State in the Union that is a Shelter State
• People in our COuntry LEGALLY are in and out of shelters, new arrivals of skilled labor – temporary assistance to get jobs that we can’t find people to fill: CNA as example
• MA has a community of shelters and medical center in the communities
• Services for people that are at risk due to past life in home countries
• Support for kids that do not speak English
• Care and location: Keep care at home or SNF at home or in the community
• Low income person at Home Hospital vs at MGB ?
• Autist kids becoming Adult – how to care for ?

 

10:15 AM – 10:40 AM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Teresa Gomez-Isla, MD, PhD, MGH, Neurology, Memory division

• Altzheimer’s biomarkers
• Clinical trials lessons on drug benefits

Panelist

David Hyman, MD, Chief Medical Officer, Eli Lilly and Company

• Cardio-metabolic – medicines redefining disease by medicines benefit to patients
• Investment in manufacturing medicines for Obesity, demand continue to expand
• Oral small molecule and scaling focus on Sleep apnea, half of the population have metabolic disease and heart failure
• Extension Program with sustained weigh loss in pre-diabetes progressing into maintained weigh loss
• Invest in R&D in the cardio-metabolic
• Listed to community feedback on experience how the drugs in AD affected patients in the Community – learning about challenges in delivery innovation in AD – irreversible neurodegenerative diseases – prevent not to loose the patients entirely – brain function
• Targeted therapies, genetic therapies
• Past life Oncologist – delivered innovations into Cancer patients – genetic medicines
• AD medicines are not accessible even to people of means, Drug delivery using PET spinal injections
• Ten years horizons at Eli Lilly is common
• Obligation to provide scientific evidence from clinical trials
• Inventory of patients qualification to participate in Clinical trials
• Oncology: Interactions in biologics, cell therapies, conjucate compounds
• Renewal of Targeting antigens
• In Oncology: Proportions of patients get long term disease control by molecules developed in Academic Centers.
• Eli Lilly acquired a BioPharma with manufacturing capabilities
• Innovations are core vs discount cash-flow, strategy is to look at the science due to capacity to develop innovations

10:40 AM – 11:20 AM

Picasso Ballroom

Disruptors

The Disruptors: Metabolic Power…Need It…Want it

Moderator

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Caroline Apovian, MD, MGH, HMS

• Last ten years, from metabolic lessons of Bariatric patients
• Treat obesity before surgery
• product composition
• multidisciplinary approach to obesity needs to be like in Oncology – multiple dsciplines
• Bariatric and weigh regain like stent stenosis after surgery
• Obesity dysfunction inflammation Gut-Brain transfer of hormones from the gut do not reach the brain to carb hunger socieaty is not signaled in the Brain and eating continued to mitigate hunger
• Insurance must cover
• Obesity Medicine – training 25 new practitioners to treat Obesity – Standards of Care, life style change
• Primary care providers do not have resources to treat Life style component of
• To reduce mortality by 20% by Bariatric surgery – No reduce of mortality by stenting – THAT I DISAGREE with

 

Panelists

David Hyman, MD, Chief Medical Officer, Eli Lilly and Company

• non-peptide agonist, bariatric level for obesity
• peptide injecting device
• hormones and peptids activan inhibitor
• hundred of million of people – scaling up
• Adolescence with obesity will develop CVD, NASH
• Epidemic of obesity the medicines are combating the epidemic
• Vials, differential pricing, orals vs injectables
• Productivity of work force, coverage by employers health insurance vs Government to handle coverage
• 10 additional drug

Xiayang Qiu, PhD, CEO, Regor Therapeutics

• six years ago, great opportunity peptide and biologics for lifetime disease of obesity
• cardiovascular favorably = affected by reduction in weigh
• Medicines that works start early at age 35

Harith Rajagopalan, MD, PhD, CEO & Co-Founder, Fractyl Health

• Diet & Life Style
• Eli Lilly and Novo Nordik – have great drugs
• Patients stop using them before they see the benefit
• durable long term of mentainance long-tern to stay on the drug
• Past life coronary cardiologist: PCI vs surgery choice of care angioplasty vs open heart surgery
• Bariatric surgery vs great medicines
• may be angioplasty for Bariatric patients
• Obesity is different than CVD
• BC-BS coverage of obesity drugs because weight is gained back vs Statins – continual use control cholestrol
• maintenance drugs in the field of Obesity are needed
• cost of drugs will come down
• more evidence on obesity drugs will affect Formulary

 

11:20 AM – 12:00 PM

Picasso Ballroom

The Innovation Gap: The Broader Impact of Metabolic Drugs on Related Diseases

Moderator

Jason Zemansky, PhD, SMid-Cap Biotech Analyst, BofA Global Research

Patrick Ellinor, MD, PhD, MGH, HMS

Panelists

Craig Basson, MD, PhD, Chief Medical Officer, Bitterroot Bio

• 17,000 patients obese no DM
• prior CVD followed 3 yrs of treatment 6% mortality during the Trial
• Death from CVD endpoint
• weight at joining the trial, loss during the trial, benefir from the drug’
• improve CVD not weigh loss
• mechanism of Inflammation – drug, reduced atherosclerosis and reduced plaque and cytokins and inflammation improve CVD status
• combination of life style and drugs GI axis systemic
• cardiac artery disease: cholesterol, inhibit inflammatory signals plaque build on top of itself – approaches to remove debris macrophages in the plaque for artherosclerosis mechanism as CVD risk

Joshua Cohen, Co-CEO, Amylyx Pharmaceuticals

• Bariatric surgery lower obesity
• genetics, eating habits,
• GLP-1 agonist developed

Punit Dhillon, CEO, Skye Bioscience

• Phase II study combination therapy CVD and Obesity
• optimize body composition – more productive on the body periphery
• subtypes metabolic gains
• Pharmacotherapy for obesity: mechanisms complementary life style change is a must have for long-term benefits
• weight loss as a start before obesity treatment
• co-morbidities of obesity

Justin Klee, Co-CEO, Amylyx Pharmaceuticals

• Parkinson’s CNS peripheral Brain access therapies
• revolution in metabolic disease treatment options, more studies for pathways to target the right patients for the right treatment
• GLP-1 is energy regulator, Hypoglycemia is very dangerous

Rohan Palekar, CEO, 89bio

• applications to obesity – data support
• bariatric surgery intervention is not enough, NASH will not be impacted only by the surgery
• NASH is a disease taking 25 years to develop
• risk of fibrosis to set in Cirrhosis which is not curable

 

• • 12:00 PM – 12:15 PM

    Break

  • 12:15 PM – 1:00 PM

    Lunch and Medicine’s Hottest Topics – Block IV of IV

Concurrent Events

• 12:15 PM – 1:00 PM

  ARPA-H: Opening New Frontiers in Health Innovations

  Panel of 5

  Glioblastoma Treatment Reinvented

  Moderators

  E. Antonio Chiocca, MD, PhD

  Chair, Department of Neurosurgery, Brigham and Women’s Hospital;

  Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School

  Charlie Yang, PhD

  Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

  Panelists

  Natalie Artzi, PhD

  Associate Professor of Medicine, Brigham and Women’s Hospital & Harvard Medical School

  Bryan Choi, MD, PhD

  Associate Director, Center for Brain Tumor Immunology and Immunotherapy, Massachusetts General Hospital;

  Assistant Professor of Neurosurgery, Harvard Medical School

  Alexandra Golby, MD

  Neurosurgeon;

  Director of Image-guided Neurosurgery, Brigham and Women’s Hospital;

  Professor of Neurosurgery, Professor of Radiology, Harvard Medical School

• 12:15 PM – 1:00 PM

  Healthcare Corporate Venture

  Moderator

  Roger Kitterman

  Senior Vice President, Ventures and Business Development & Licensing, Mass General Brigham

  Managing Partner, Mass General Brigham Ventures

  Panelists

  Rahul Ballal, PhD

  CEO, Mediar Therapeutics

  Tim Luker, PhD

  VP, Ventures & West Coast Head, Eli Lilly

  James Mawson

  CEO, Global Corporate Venturing

• 12:15 PM – 1:00 PM

  Inflammation Pathways

  Moderators

  Tazeen Ahmad

  SMid-Cap Biotech Analyst, BofA Global Research

  Katherine Liao, MD

  Associate Physician, Department of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital;

  Associate Professor of Medicine and Biomedical Informatics, Harvard Medical School

  Panelists

  Jessica Allegretti, MD

  Director, Crohn’s and Colitis Center, Brigham and Women’s Hospital;

  Associate Professor of Medicine, Harvard Medical School

  Andrew Luster, MD, PhD

  Chief, Division of Rheumatology, Allergy and Immunology;

  Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital;

  Persis, Cyrus and Marlow B. Harrison Professor of Medicine, Harvard Medical School

  Thorsten Mempel, MD, PhD

  Associate Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital;

  Professor of Medicine, Harvard Medical School

• 12:15 PM – 1:00 PM

  Hospital at Home

  Moderators

  Joanna Gajuk

  Health Care Facilities and Managed Care Analyst, BofA Global Research

  Heather O’Sullivan, MS, RN, AGNP

  President, Mass General Brigham Healthcare at Home

  Panelists

  O’Neil Britton, MD

  Chief Integration Officer & Executive Vice President, Mass General Brigham

  Jatin Dave, MD

  Chief Medical Officer, MassHealth;

  Director of Clinical Affairs, UMass Chan Medical School

  Chemu Lang’at

  Chief Operating Officer, Best Buy Health

1:05 PM – 1:45 PM

Picasso Ballroom

Pioneering Digital Transformation

Moderator

Liz Kwo, MD, Chief Commercial Officer, Everly Health

• Infrastructure
• AI used for

Panelists

Anna Åsberg, Vice President, AstraZeneca Pharmaceuticals

• Massive data bases organize
•  AI to augment intelligence inside the data

Tyler Bryson, Corporate Vice President, US Health & Public Sector Industries, Microsoft Corporation

• Do we have platforms to serve new problem
• Regulatory changes require visiting use cases
• Pharma has the research data, providers have EMR – Microsoft builds new models using that data
• Tumor imaging data was processed and new pattern recognition done on data of these tumors. New patterns are now a subject for research, just identified inside the data
• Trust in Healthcare
• NYC and Microsoft developed a System for small businesses to access city resources
• Works with Academic institutions: Programs at Harvard and Princeton to train students by Microsoft employees on MIcrosoft AI technologies that as they graduate there will be trained new AI-trained employees
• collaborations

Aditya Bhasin, BofA

• AI in Banking: Bias, security
• AI virtual system analytics to provide insight for scaling

Jane Moran, MGH

• Network, Data structure needs updates
• technology to help clinicians
• care team to work with Generative AI to assist in e-mail reading and problem solving
• Healthcare equity – avoid Bias
• AI is not an answer to every problem
• innovate at scale: using Epic and Microsoft
• Clinical data structure for LLM, AI to renovate administrative processes inside MGH
• Data structure for transperancy
• Digital Rounds like Medical ROunds audit problems
• equity in data

1:45 PM – 2:25 PM

Picasso Ballroom

Capital Formation: Putting Money to Work – State of Affairs in Capital Markets

Moderators

John Bishai, PhD, BofA

• valuations went down

Brendan Singleton, Healthcare Equity Capital Markets, BofA Securities

• what impact Capital flow

Emma Somers-Roy, Chief Investment Officer, Mass General Brigham

Panelists

Chris Garabedian, Chairman & CEO, Xontogeny; Venture Portfolio Manager, Perceptive Advisors

• Valuations done with comparables for IPO
• Not quick to invest in companies, responsible behavior
• Private rounds, Biotech and Pharma strategic partners
• M&A stable requires are exciting valuation
• foundations, institutional investors – level of interest is related to valuations number of years to exit
• Peak sale, Public markets different than Private markets
• Obesity is a crowd space, diferentiation is important
• Exit tow ways: year for IPO natural acquirer – Who is he??
• Cancer was a dominant now CNS, Cardio-metabolic, ophthalmology
• size of market – Cancer was attractive, less in 2024
• Early venture investor: 50-100MM valuation to 2Bil
• CMS has discounting since profits are been realize at present time
• Patents`
• Presidential election
• investors scarce pushed fewer mega rounds 100MM financing requires early clinical data
• Hedge fund very conservative with valuations
• Downsize in Biotech is over

Arjun Goyal, MD, Vida Ventures

• Investment in private markets
• 2019-2021 – IPOs on narratives and proof of concept, only only, no financials
• M&A or Partnering – financial risk clinical data point
• validation of team success
• size of market is very important
• Innovation matters always in Pharma, prospects for Biotech very bright
• what is HOT in a moment
• combination therapies
• Life cycle: compound right gene, financing history, fundamentals
• calibration of market valuations

 

2:25 PM – 2:50 PM

Picasso Ballroom

Fireside

Lessons Learned Shaping New Horizons: Visionary Change Agent Perspectives

Moderator

Yvonne Hao, Secretary of Economic Development, Commonwealth of Massachusetts

• accelerate AI adoption by nurses, How do you do that??
• Public private partnerships
• If you have a blank slate – do it differently

Great impact of Cleveland Clinic

Panelists

Delos “Toby” Cosgrove, MD, Executive Advisor; former CEO & President, Cleveland Clinic

• Housing, education, research beyond healthcare
• Reduce cost in healthcare, call centers by AI: equipment to measure BP every 4 hours
• Technology is approved 13 years to become standard of care
• COST in healthcare requires SALVATION
• mistakes by leadership
• Regulators have their share in current situation of Healthcare
•  Leadership in Health care must change

Marc Harrison, MD, Co-founder & CEO, Health Assurance Transformation Corp. (HATCo)

• collaborate with competitors
• AI is a tool not a solution
• Streamline processes to reduce costs
• Government should not solve the Healthcare problem
• Residents are victims of leaders mistakes
• Only healthcare industry sees the medical records of all the population
• gene therapy, innovations to change healthcare and get financial solvency

2:50 PM – 3:15 PM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

Andrew Bressler, Washington Healthcare Policy Analyst, BofA Global Research

• What is coming up in the next two years
• Are you growing and Hiring?

Yvonne Hao, Secretary of Economic Development, Commonwealth of Massachusetts

• AI – what is the potential for Healthcare
• MA to work with ARPA-H

Panelist

Renee Wegrzyn, PhD, Director, Advanced Research Projects Agency for Health – A Federal Governmental Agency

• ARPA-H Model was introduce under the Advanced Research Projects Agency for Health
• Hired 21 Program Managers to manage Health initiatives in research
• Health is not a partizan affair
• Bring young innovators, mantored by experiences healthcare professionals
• cellular therapeutics is an example selected to advanced the field
• Data driven – looking at +100 project approved by government agency
• Governtment, Academia, Private sector – SOLICITATIONS for solving a research problem
• Technical merit in judging applications
• Value-baced pricing – data to influence policy FDA, NIH collaboration
• FDA to finance projects spending
• Pediatrics
• President announced a program for ARPA-H to work on
• Investors are welcome to review proof of concepts of ARPA-H
• Return on Investment for all Americans’ Tax payers money
• Yes, growing and hiring. $1.5 milion budget

 

 

3:15 PM – 3:20 PM

First Look

First Look Award Presentation

3:20 PM – 3:35 PM

Selector of Winner: Doug Marshall & Paul Anderson, MD, PhD

• Leigh Hochberg, MD, PhD @harvardmed
• John Hanna, MD, PhD @harvardmed

 

Afternoon Break

3:35 PM – 4:15 PM

Picasso Ballroom

Disruptors

The Disruptors: The Biologic Revolution in Radiotherapies

Moderator

John Bishai, PhD, Global Healthcare Investment Banking, BofA Securities

Umar Mahmood, MD, PhD, MGH, HMS

Panelists

Amos Hedt, Chief Business Strategy Officer, Perspective Therapeutics

• imaging used to deliver the therapeutics before the drug touch the patient to calculate toxicity
• PL-1 combined with radiotherapy synergistics results
• immunogenic combination therapy, in presence of these agents, immune response reaction in the immune cells

Matthew Roden, PhD, President & CEO, Aktis Oncology

• Conjugates – delivery direct to tumors
• Opportunity two targets: (1) SSTA2 marker (2) xx
• WHen agent inside the tumor, shrinkage and no emergence of cell nascent 
•  optimization design
• Treatment break for patients and families

Philip Kantoff, MD, Co-Founder & CEO, Convergent Therapeutics

• Radio-pharmeceutics : 10 days half-life carrier not a target for small molecules Data on 120 patient, namo robust response synergy of antibody and molecule
• image alphas
• durable responses

Matt Vincent, PhD, AdvanCell Isotopes

• ROS species generated in the tumor
• peptides, protein binders
• paradigm shift in delivery of oncology therapeutics directly to tumors

Lena Janes, PhD, Abdera Therapeutics

• isotope will deliver the payload without damaging the DNA and healthy tissue
• target different types of tumors, different half-life
• Radiation therapy using isotopes id one of two modalities: tumor in and tumor out approach
• screen for patient for the translational therapy
• Next generation of products will come, now it is the beginning of these agents

4:20 PM – 4:45 PM

Picasso Ballroom

Fireside

Fireside Chat

Moderator

Michael Ryskin, Life Science Tools & Diagnostics Analyst, BofA Global Research

• Precision Medicine was it a paradigm shift??
• Acquisition of manufacturing capabilities
• research, manufacturinf line blurred
• WHat excites you the most

Panelist

Marc Casper, Chairman, President & CEO, Thermo Fisher Scientific

• Enabling Life sceinces, Pharmaceutical industries $1.5Billion internal investment annually
• AI increasing knowledge
• How is Precision Medicine applied? Sequencing in Cancer accelerated the Genomics information in use for 24 hours response of the sequence – adopted around the World.
• at MGH lung cancers are treated with genomic sequencing
• identification of the patients suitability for a targeted treatment
• treatment during pregnacy at home vs hospitalization
• History of company: Tools first: Mass spectrometry, one year for one sequence, protein identification and carrying to Mass spectrometry
• Interactions need understanding acquiring electro spectrometry allowing analytical chemistry on proteins
• Broad range of products: Clinical research to meet regulatory requirements entry into Reagents products.
• Clinical Trials made effective by Thermo Scientific Products
• Capabilities in registries, patient safety in psoriasis
• Large role in experimental medicine drives efficiency in LABS
• SIze of customers: small Biotech and large Pharma
• Manufacture medicines: work with partnersbuilt by acquisitions small molecules,
• 100 engagements research, supply chain making medicines available at sites
• Role for AI at Thermo Scientific:

1. Productivity – Cost effective for processes in use by 120,000 employees
2. Super customer interaction perfected by interogations with internal manuals to provide answers quickly
3. Improvement of products

• Excitement Points: Responsiveness to COVID pandemic
• New medicine development

4:50 PM – 5:30 PM

Picasso Ballroom

The Reemergence of ADCs, Precision Medicine, T-cell engagers, and Bispecifics: Oncology at Its Finest

 

Moderators

John Bishai, PhD, BofA

• Approach to AI
• Strategy regarding clinical trial design, vs molecule design

Justin Gainor, MD, MGH, HMS

• How strategies are developed and then modified?
• immune therapies work better open new paradeigm

Panelists

Moitreyee Chatterjee-Kishore, PhD, Head of Development, Immuno-Oncology and Cancer Cell Therapy, Astellas Pharma Inc.

• cancer – first line of treatment vs 2nd and 3rd
• Precision medicine more precise
• mix and match immunotherapy and other modalities
• small molecule early on
• molecule formulation is science and art
• Stratify the patient population early on
• Help needed to design better trials
• Research is key for molecule design

Niall Martin, PhD, CEO, Artios Pharma

• peptide chemistry
• molecule design had options several are applied
• biomarker driven event in development cycle
• strategy of biomarkers – lack structure
• effect of combination therapy on survival?

Chris Varma, PhD, Co-founder, Chairman & CEO, Frontier Medicines

 

5:30 PM – 8:30 PM

South Lawn Tent

Attendee Reception and Dinner

Moderator

Anne Oxrider

Senior Vice President, Benefits Executive, Bank of America

Panelist

Deepak Chopra, MD

Founder, The Chopra Foundation

Wednesday, September 25, 2024

• 7:30 AM – 11:00 AM

  Rotunda

  Registration

• 7:30 AM – 8:30 AM

  Picasso Foyer

  Continental Breakfast

8:30 AM – 8:55 AM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

David Ting, MD, Associate Clinical Director for Innovation, Mass General Cancer Center; Associate Professor of Medicine, Harvard Medical School

• Innovation is the foundation of the future
• Creative thinking vs one agent and one target
• Openness is much appreciated

Jason Zemansky, PhD, SMid-Cap Biotech Analyst, BofA Global Research

• On WSJ article on M&A in Biotech attributing decline in M&A of Biotech companies due to LACK of Innovations
• Q from audience: organizational structure and innovation
• Vision on leveraging Partnerships

Panelist

Tadaaki Taniguchi, MD, PhD, Chief Medical Officer, Astellas Pharma

• Pharma and Biotech heavy betting on new medicines in Oncology
• Astellas Pharma is different than other Pharma companies
• We focus on Oncology and in combination therapies as a priority
• Investment pay attention to Leadership priorities
• One product vs BEST combination therapy for best treatment and outcomes
• Innovations come from anywhere
• ADCs: Target, payload emerged recently by a partnership
• Collaborations: several pathways, several modalities, several combinations therapies
• Partnership requires greater flexibility
• Created Small flexible Labs to enable to innovate with Partners, “we can’t innovate alone”

9:00 AM – 9:40 AM

Picasso Ballroom

Disruptors

The Disruptors: The Role of Pathway Inhibition in Inflammation and Inflammatory Diseases

Moderators

Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Global Research

• Are you using AI
• Neuroinflammation

Cynthia Lemere, PhD, BWH, HMS

• What systems are primarily impacted by the Immunes system
• Drug delivery for inflammation huge area
• Getting antibodies to the Brain
• Precision medicine, genetics,specific person with specific immune disease

Panelists

Jo Viney, PhD, Cofounder, President & CEO, Seismic Therapeutic

• Pandemics highlighted the impact of the immune system
• Targeting cytokines in specific locations – hew approach
• Modalities on hand: protein degradation mediation by bringing two cells together
• AI is used for Patient stratification
• AI to be used in Pathways involved in disease process to identify Biologics, PROTAC,
• AI and ML for training models from interaction between proteins
• ChatGPT to predict interactions among proteins
• Immune disease and remission bust the immune system to improve quality of life of patient undergoing interventions
• T-cell engaggers – in cases of refractory – great approach for boosting the immune system: removal of antibidies, recycling antibodies,
• Two ends: Cell depletion vs Early detection
• Therapy is every 6 months, cell depletion takes 3 months to come back.
• Target immune system in the periphery,
• Immune system in neurodegenerative diseases: Parkinson’s local modulation to penetrate neurological system
• Markers to cross the BBB or not cross in neurological diseases
• Immune disease is POLYGENIC multiple o=etiologies, mutation, genetics, which cell and which pathway to target a therapeutics: Biologics
• Patient stratification is key for Precision Medicine at the cell level
• T-cell, B-cell, Cytokines and antibodies mediated disease
• ADGs degradation

9:45 AM – 10:10 AM

Picasso Ballroom

H. Jeffrey Wilkins, MD, Abcuro

• Inflammation play a role in activating the immune system
• zin the days of Medical School: inhibition of cytokines
• Today: specificity to target cells for depletion
• Specific biomarkers for response to therapies
• cell types by mutations and physiology and causality in the inflammation area: we know why they have inflammation we need to learn interventions for inflammation
• Asthma in the 40s as an inflammatory disease
• assess treatment of inflammation
• Neuro-inflammation – not well understood
• What is the cause that drive the disease: understanding encephalitis?

NiranJana Nagarajan, PhD, MGB Ventures

• Biology is the driver not AI
• depletion of cells in a certain stage
• Translation from disease to other diseases in the case of cell therapy potential – active area companies are trying solutions
• Inflammation is a huge challenge to treat

 

Fireside

Fireside Chat

Moderators

Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, Brigham and Women’s Hospital; Harriet Ryan Albee Professor of Medicine, Harvard Medical School

• Pathways in vaccine design
• How to educate population on Vaccines
• other approaches than vaccines

Alec Stranahan, PhD, SMid-Cap Biotech Analyst, BofA Global Research

• Vaccine approval
• Next generation vaccines

Panelist

Stéphane Bancel, CEO, Moderna

• Vaccine design: long term vaccines weakens in aged population
• data on role of AVV in Multiple Sclerosis
• working on in the US vs France, Netherland in Europe different approaches
• Vaccine for HIV
• Vaccine was approved last year for children, pharmacies shortage
• Season of FLu three times more vaccines in use
• Employees run vaccine clinics on site
• Vaccines not related to COVID
• Misinformation from COVID vaccine
• 5% of COVID hospitalized were on the booster
• Combination vaccines for high risk populations
• Healthcare providers need to be involved in Education, many do not have an interest in the education on vaccines
• Local stories from Vaccine manufectures and developer to be used in education in the communities
• Individual DNA cancer celll signature of the cancer  – data over time for development of vaccine to cancer many more tumor types are needed
• Checkpoints in early disease
• biopsy are too expensive
• Side effect studies going on
• mono-therapy vs immunotherapy costs involved
• Naive virus to get into the Liver two diseases – cassets for sose management
• Recombinant antibodies technology from the 70s
• PD-1
• COVID – was nto in the plan for development – design in silicon in two weeks – no change after this design

• 10:10 AM – 10:20 AM

  Break

10:20 AM – 11:00 AM

Picasso Ballroom

The Innovation Gap: Understanding the Role of Cell Therapies in Autoimmune Disease

Moderator

Charlie Yang, PhD

Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

• TCM
• CAR-T
• advantages of each cell type

Angele Shen, MGB Innovations

• CAR-T
• What would be a quick breakthrough?

Panelists

Jeff Bluestone, PhD, CEO & President, Sonoma Biotherapeutics

• Cell therapy for cell depletion elimination of B-cells like its role in Multiple Sclerosis
• Working with regulatory T-cells
• Population of cells to study: T-cells master regulator in multiple ways – produce metabolic factors, infection tone in activation of other cells
• Biology of cell: RNA, DNA
• TCR – target antigens in tissues they are in in immune suppression
• FInding the right peptide bindes to a certain MAC
• CAR-T – recornize the cells in the local milieu like in patients with RA as an autoimmune disease
• Clinical models ascertain cell types involvement leading to clinical trial insights then to therapies on a decision tree
• recent data on CAR-T immune response in allogeneic for potential use in neurodegenerative diseases
• patients and companies over react on immune therapy: Patients and Science vs hype
• next generation: POC,
• Gene therapy specificities vs Cell therapies – each approach will develop a different drug
• FDA and NIH has in 11/2023 a meeting on Regulation of Cell therapy on stability and their approach to immune disease where there are already several drugs
• approvals challenges companies
• Price, too expensive a treatment is cell therapy

Chad Cowan, PhD, Executive Advisor, Century Therapeutics

• use Natural Killer cells to elicit long-term immune response, T-cells,
• active Beta cells]Regulatory monitoring use
• DM – regulatory cells made from Stem cells
• mission durable response
• Clinical issues – not easy way for treatment wiht a cell line and bioreactors and modalities less similar to autologoous celles
• CAR-T in oncology lessons now are transferred to Immune disease
• Cell therapy requires technologies to mature multiple modalities and multiple drugs not one cell therapy for all immune diseases
• Stability of the therapy vs rejection by immune system
• FDA making cells is not as making drugs – higher level of scrutiny for cell therapy
• SYNTHETIC BIOLOGY on B-cells for future breakthrough

Samantha Singer, President & CEO, Abata Therapeutics

• Immune response involve many cell types in many diseases
• Oncology the use of T-cells as tissue residents staying in tissue long time
• Specific biology of the disease and regulatory cells receptors optimizing TCR presentation in pathology of tissue residents phyno types
• activate in nervous system or in pancreas – intersection of cell biology with disease biology
• Market feasibility – scaling, biology, pathology for reimbursement
• antibody therapy may be appropriate than cell therapy is only a novel option
• Cell manufacturing requires optimization of process, companies commercializing across all cell types
• comprehensive approach for systemic immune suppression
• : healthy tissue vs diseased tissue with cell theray implanted cells as residents in tissue
• clinical data on product performance and on the biology reactions

11:00 AM – 11:40 AM

Picasso Ballroom

Unmet Clinical Needs: 100 Harvard KOLs Weigh In

Moderators

Jose Florez, MD, PhD, Physician-in-Chief and Chair, Department of Medicine, Massachusetts General Hospital; Professor, Harvard Medical School

• 40 minutes to deal with big needs collected from 100 faculties at Harvard Medical School
• The ten issues on one slide
• How could we use compute to distill data

Bruce Levy, MD, Physician-In-Chief and Co-Chair, Department of Medicine, Brigham and Women’s Hospital; Parker B. Francis Professor of Medicine, Harvard Medical School

• Transformation from the Present to the Future
• identifying the needs
• Infectious diseases: Rapid diagnostics need
• resistance to antibiotics and metabolic reactions endogenous
• Pandemics globally of diseases erradicated in the past: Pox, polio
• Improving health in Geriatrics, not population growing but geriatric population growing. Beyong age 60 a citizen will use 1 or 2 physicians each
• 7,000 diseases, Genetic diseases requires integration and innovations in therapy
• Innovations in Home devices

Panelists

Rox Anderson, MD, Lancer Endowed Chair of Dermatology;, Director, Wellman Center for Photomedicine, MGH; Professor of Dermatology, HMS

• Access to data across institutions

Nicole Davis, PhD, Biomedical Communications

• We asked 104 expert practitioners, content collected was analyzed

1. detection early
2. keeping the Human brain healthy
3. geriatrics Medicine, aging and compound effects on health system with aging and Health equity

• Bias in Data

Jean-François Formela, MD, Partner, Atlas Venture

• genetic information used in therapeutics design

Steven Greenberg, MD, Neurologist, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School

• Human genome completed in 1999, human genetic diseases were discovered learn about the disease at the tissue level with genomics and a system approach
• Pathogenic drivers, systme integration by therapeutics approaches to pathways multiple cytokines in allergic reactions Pfizer had two biomarkers and therapies for systemic biology of disease
• Pediatrics has its own challenges
• Imaging medicine
• Living longer at a lower cost  – HOW TO ACHIEVE THAT?
• growth abnormality in children: Body growth and Skull shrink

John Lepore, MD, CEO, ProFound Therapeutics;, CEO-Partner, Flagship Pioneering

• Pathway, targeting therapy to patients in a System biological approach
• Database of systme biology has missing components not included in the Human genome project – completion of the Data
• Definition of End points needs revisiting
• Identifying specific populations vs getting quickly to market
• Diseases of aging: Muscles diseases – how to promote improvement in muscle mass

CONCLUSIONS

1. Gray Tsunami
2. Brain health
3. Cancer treatment paradigm shift
4. Fibrosis in many diseases
5. infectious disease in changing World
6. Equity in HC
7. Clinical Data is VAST
8. Systemic view of Human disease
9. New approaches to Psychaitry
10. Rare disease treatment needs a charter

In addition,

• new generation of pain treatment
• skin treatment new drugs
• Chronic disease: improve treatment and prevention.
• Obesity medicine – new discipline in a new Era

11:45 AM – 12:30 PM

Picasso Ballroom

Fireside

Fireside Chat

Moderators

Tazeen Ahmad, SMid-Cap Biotech Analyst, BofA Global Research

• FDA sets criteria  – How is that done?
• Autoimmune disease therapies – What is in the horizon?

 

Paul Anderson, MD, PhD, Chief Academic Officer, Mass General Brigham;

• drug development
• drug pricing in Europe
• New book
• RA needs more medicines

UNCONTROLLED SPREAD

In Uncontrolled Spread, a New York Times Best Seller, Dr. Scott Gottlieb identifies the reasons why the US was caught unprepared for the pandemic and how the country can improve its strategic planning to prepare for future viral threats.

Panelist

Scott Gottlieb, MD, Physician; Former Commissioner, Food and Drug Administration (2017-2019)

• FDA approval 1st gene therapy in his tenure
• Price of drugs: efficatious vs time to deveop
• competitors in the marketplace are there for market share
• New Book: Episodes in the FDA, appproval process at FDA, Gene therapy 1st in class approved – a special moment. Back in 1980s era translated to antibodies, to T-cell pioneering work.
• Publisher worried it will not sell very well
• FDA had concerns about manufacturing aspects
• In 2024 we understand Biologics on novel platforms
• Worries that Medicare will not reimbursement  and cover the new therapies: Cell therapy
• Statins approval had a known very large market vs Cell therapy not known which Cancer patients will benefit???
• Black box involved in Autoimmune, studies bring exciting results
• In 2018 – needs arise for early approved of drugs in AD, amyloid plaque – change in thinking and is controversial
• In early 2020, change in settings of clinical trials, placido no more the only way for Randomized trials
• Approval for AD drug vs othe indication – the process is difference (DMD a case to think about)
• AI & NLP: Train on data of 10,000 lesions
• FDA choose not to regulate AI the physician is in the Middle
• Who is wrong: CHatGPT or the clinician ?
• Data set on gene may represents NEW biologies that Physicians had not seen before
• Data validation on medical devices and their approval after regulating them
• Diagnostics tests: Validation Panels are involved
• Regulated on input data vs Output data and validate the input data
• Platforms are needed for regulation of AI involvement in the drug discovery and the drug approval process
• investment in this platforms will be done by Whom?? It will come
• Framework for AI at FDA: Regulatory gray data for applications and standards for output – not a novel regulatory concept
• If AI will be applied widely, I/O accuracy is a must have
• may be achievable soon?
• FDA is evolutionary organization in its decision process NOT a REVOLUTIONARY organization. Simulation work started in 2003, 40 people doing that then.
• Recently, new team in Agency working of Safety with tools and technologies that are common in Science  – Approvals to drug labels and off labels that 20 years ago would not have happened
• Tolerance for higher prices is to support Private sector that brings the innovating drugs to market

 

• 12:30 PM – 12:35 PM

  Picasso Ballroom

  Closing Remarks

   

SPEAKERS

C-Suite Speakers

Faraz Ali

CEO, Tenaya Therapeutics

Peter Anastasiou

CEO, Capsida Biotherapeutics

Paul Anderson, MD, PhD

Chief Academic Officer, Mass General Brigham; K. Frank Austen Professor of Medicine, Harvard Medical School

Rahul Ballal, PhD

CEO, Mediar Therapeutics

Stéphane Bancel

CEO, Moderna

Craig Basson MD, PhD

Chief Medical Officer, Bitterroot Bio

Jeff Bluestone, PhD

CEO & President, Sonoma Biotherapeutics

Albert Bourla, PhD

Chairman & CEO, Pfizer

O’Neil Britton, MD

Chief Integration Officer & Executive Vice President, Mass General Brigham

Marc Casper

Chairman, President & CEO, Thermo Fisher Scientific

Joshua Cohen

Co-CEO, Amylyx Pharmaceuticals

Delos “Toby” Cosgrove, MD

Executive Advisor; former CEO & President, Cleveland Clinic

Jatin Dave, MD

Chief Medical Officer, MassHealth; Director of Clinical Affairs, UMass Chan Medical School

Punit Dhillon

CEO, Skye Bioscience

Steve Favaloro

Chairman & CEO, Genezen

John Fish

Chairman & CEO, Suffolk

Alexandria Forbes, PhD

CEO, MeiraGTx

Niyum Gandhi

CFO & Treasurer, Mass General Brigham

Chris Garabedian

Chairman & CEO, Xontogeny; Venture Portfolio Manager, Perceptive Advisors

Lucas Harrington, PhD

Co-Founder & CSO, Mammoth Biosciences

Marc Harrison, MD

Co-founder & CEO, Health Assurance Transformation Corp. (HATCo)

Amos Hedt

Chief Business Strategy Officer, Perspective Therapeutics

Rod Hochman, MD

President & CEO, Providence

David Hyman, MD

Chief Medical Officer, Eli Lilly and Company

Philip Kantoff, MD

Co-Founder & CEO, Convergent Therapeutics

Daniel Karlin, MD

Chief Medical Officer, MindMed

Reshma Kewalramani, MD

CEO & President, Vertex Pharmaceuticals

Justin Klee

Co-CEO, Amylyx Pharmaceuticals

Anne Klibanski, MD

President & CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Samarth Kulkarni, PhD

CEO, CRISPR Therapeutics

Liz Kwo, MD

Chief Commercial Officer, Everly Health

Adam Landman, MD

Chief Information Officer & SVP, Digital, Mass General Brigham; Associate Professor of Emergency Medicine, Harvard Medical School

Chemu Lang’at

Chief Operating Officer, Best Buy Health

Paul LaViolette

Managing Partner & COO, SV Health Investors

John Lepore, MD

CEO, ProFound Therapeutics; CEO-Partner, Flagship Pioneering

Christopher Longhurst, MD

Chief Medical & Digital Officer, UC San Diego Health

Kevin Mahoney

CEO, University of Pennsylvania Health System

Niall Martin, PhD

CEO, Artios Pharma

James Mawson

CEO, Global Corporate Venturing

Mark McKenna

Chairman & CEO, Mirador Therapeutics

Jane Moran

Chief Information and Digital Officer, Mass General Brigham

William Morris, MD

Chief Medical Information Officer, Google Cloud

Rohan Palekar

CEO, 89bio

Raju Prasad, PhD

Chief Financial Officer, CRISPR Therapeutics

Xiayang Qiu, PhD

CEO, Regor Therapeutics

Harith Rajagopalan MD, PhD

CEO & Co-Founder, Fractyl Health

Shiv Rao, MD

CEO & Founder, Abridge

Kerry Ressler, MD, PhD

Chief Scientific Officer, McLean Hospital; Professor of Psychiatry, Harvard Medical School

Matthew Roden, PhD

President & CEO, Aktis Oncology

Sandi See Tai, MD

Chief Development Officer, Lexeo Therapeutics

Samantha Singer

President & CEO, Abata Therapeutics

Joanne Smith-Farrell, PhD

CEO & Director, Be Biopharma

Emma Somers-Roy

Chief Investment Officer, Mass General Brigham

Adam Steensberg, MD

President & CEO, Zealand Pharma

Tadaaki Taniguchi, MD, PhD

Chief Medical Officer, Astellas Pharma

Elsie Taveras, MD

Chief Community Health & Health Equity Officer, Mass General Brigham; Conrad Taff Endowed Chair and Professor of Pediatrics, Harvard Medical School

Jo Viney, PhD

Cofounder, President & CEO, Seismic Therapeutic

Ron Walls, MD

Chief Operating Officer, Mass General Brigham; Neskey Family Professor of Emergency Medicine, Harvard Medical School

Christophe Weber

President & CEO, Takeda

Fraser Wright, PhD

Chief Gene Therapy Officer, Kriya Therapeutics

Speakers

Anna Åsberg

Vice President, AstraZeneca Pharmaceuticals

Tazeen Ahmad

SMid-Cap Biotech Analyst, BofA Global Research

Jessica Allegretti, MD

Director, Crohn’s and Colitis Center, Brigham and Women’s Hospital; Associate Professor of Medicine, Harvard Medical School

Rox Anderson, MD

Lancer Endowed Chair of Dermatology; Director, Wellman Center for Photomedicine, MGH; Professor of Dermatology, HMS

Katherine Andriole, PhD

Director of Academic Research and Education, Mass General Brigham Data Science Office; Associate Professor, Harvard Medical School

Caroline Apovian, MD

Co-Director, Center for Weight Management and Wellness, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Vanita Aroda, MD

Director, Diabetes Clinical Research, Brigham and Women’s Hospital; Associate Professor, Harvard Medical School

Natalie Artzi, PhD

Associate Professor of Medicine, Brigham and Women’s Hospital & Harvard Medical School

John Bishai, PhD

Global Healthcare Investment Banking, BofA Securities

David Blumenthal, MD

Professor of Practice of Public Health and Health Policy, Harvard TH Chan School of Public Health; Research Fellow, Harvard Kennedy School of Government; Samuel O. Thier Professor of Medicine, Emeritus, Harvard Medical School

Giles Boland, MD

President, Brigham and Women’s Hospital and Brigham and Women’s Physicians Organization; Philip H. Cook Distinguished Professor of Radiology, Harvard Medical School

Andrew Bressler

Washington Healthcare Policy Analyst, BofA Global Research

James Brink, MD

Enterprise Chief, Radiology, Mass General Brigham; Juan M. Taveras Professor of Radiology, Harvard Medical School

David Brown, MD

President, Academic Medical Centers, Mass General Brigham; Mass General Trustees Professor of Emergency Medicine, Harvard Medical School

Tyler Bryson

Corporate Vice President, US Health & Public Sector Industries, Microsoft Corporation

Jonathan Carlson, MD, PhD

Director of Chemistry, Center for Systems Biology, Massachusetts General Hospital; Assistant Professor of Medicine, Harvard Medical School

Miceal Chamberlain

President of Massachusetts, Bank of America

Moitreyee Chatterjee-Kishore, PhD

Head of Development, Immuno-Oncology and Cancer Cell Therapy, Astellas Pharma Inc.

Dong Feng Chen, MD, PhD

Associate Scientist, Massachusetts Eye and Ear; Associate Professor, Harvard Medical School

Jasmeer Chhatwal, MD, PhD

Associate Neurologist, Massachusetts General Hospital; Associate Professor of Neurology, Harvard Medical School

E. Antonio Chiocca, MD, PhD

Chair, Department of Neurosurgery, Brigham and Women’s Hospital; Harvey W. Cushing Professor of Neurosurgery, Harvard Medical School

Bryan Choi, MD, PhD

Associate Director, Center for Brain Tumor Immunology and Immunotherapy, Massachusetts General Hospital; Assistant Professor of Neurosurgery, Harvard Medical School

Deepak Chopra, MD

Founder, The Chopra Foundation

Yolonda Colson, MD, PhD

Chief, Division of Thoracic Surgery, Massachusetts General Hospital; Hermes C. Grillo Professor of Surgery, Harvard Medical School

Chad Cowan, PhD

Executive Advisor, Century Therapeutics

Cristina Cusin, MD

Director, MGH Ketamine Clinic and Psychiatrist, Depression Clinical and Research Program, Massachusetts General Hospital; Associate Professor in Psychiatry, Harvard Medical School

Nicole Davis, PhD

Biomedical Communications

Marcela del Carmen, MD

President, Massachusetts General Hospital and Massachusetts General Physicians Organization (MGPO); Executive Vice President, Mass General Brigham; Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Gerard Doherty, MD

Surgeon-in-Chief, Mass General Brigham Cancer; Surgeon-in-Chief, Brigham and Women’s Hospital; Moseley Professor of Surgery, Harvard Medical School

Liz Everett Krisberg

Head of Bank of America Institute

Maurizio Fava, MD

Chair, Department of Psychiatry, Massachusetts General Hospital; Slater Family Professor of Psychiatry, Harvard Medical School

Keith Flaherty, MD

Director of Clinical Research, Mass General Cancer Center; Professor of Medicine, Harvard Medical School

Jose Florez, MD, PhD

Physician-in-Chief and Chair, Department of Medicine, Massachusetts General Hospital; Professor, Harvard Medical School

Jean-François Formela, MD

Partner, Atlas Venture

Fritz François, MD

Executive Vice President and Vice Dean, Chief of Hospital Operations, NYU Langone Health

Joanna Gajuk

Health Care Facilities and Managed Care Analyst, BofA Global Research

Jason Gerberry

Specialty Pharma and SMid-Cap Biotech Analyst, BofA Global Research

Gad Getz, PhD

Director of Bioinformatics, Krantz Center for Cancer Research and Department of Pathology; Paul C. Zamecnik Chair in Cancer Research, Mass General Cancer Center; Professor of Pathology, Harvard Medical School

Alexandra Golby, MD

Neurosurgeon; Director of Image-guided Neurosurgery, Brigham and Women’s Hospital; Professor of Neurosurgery, Professor of Radiology, Harvard Medical School

Allan Goldstein, MD

Chief of Pediatric Surgery, Massachusetts General Hospital; Surgeon-in-Chief, Mass General for Children; Marshall K. Bartlett Professor of Surgery, Harvard Medical School

Scott Gottlieb, MD

Physician; Former Commissioner, Food and Drug Administration (2017-2019)

David Grayzel, MD

Partner, Atlas Venture

Steven Greenberg, MD

Neurologist, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School

Steven Grinspoon, MD

Chief, Metabolism Unit, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

Daphne Haas-Kogan, MD

Chief, Enterprise Radiation Oncology, Mass General Brigham; Professor, Harvard Medical School

Roger Hajjar, MD

Director, Gene & Cell Therapy Institute, Mass General Brigham

John Hanna, MD, PhD

Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

Yvonne Hao

Secretary of Economic Development, Commonwealth of Massachusetts

Nobuhiko Hata PhD

Director, Surgical Navigation and Robotics Laboratory, Brigham and Women’s Hospital; Professor of Radiology, Harvard Medical School

Maura Healey

Governor of the Commonwealth of Massachusetts

Elizabeth Henske, MD

Director, Center for LAM Research and Clinical Care, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Leigh Hochberg MD, PhD

Director of Neurotechnology and Neurorecovery, Massachusetts General Hospital; Senior Lecturer on Neurology, Harvard Medical School

Daphne Holt, MD, PhD

Director of the Resilience and Prevention Program, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School

Susan Huang, MD

EVP, Chief Executive, Providence Clinical Network, Providence Southern CA

Keith Isaacson, MD

Director of Minimally Invasive Gynecologic Surgery and Infertility, Newton Wellesley Hospital; Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School

Ole Isacson, MD-PhD

Founding Director, Neuroregeneration Research Institute, McLean Hospital; Professor of Neurology and Neuroscience, Harvard Medical School

Haim Israel

Head of Global Thematic Investing Research, BofA Global Research

Farouc Jaffer, MD, PhD

Director, Coronary Intervention, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Russell Jenkins, MD, PhD

Krantz Family Center for Cancer Research, Massachusetts General Hospital; Mass General Cancer Center, Center for Melanoma; Assistant Professor of Medicine, Harvard Medical School

Hadine Joffe, MD

Executive Director of the Connors Center for Women’s Health and Gender Biology; Interim Chair, Department of Psychiatry, Brigham and Women’s Hospital; Paula A. Johnson Professor of Psychiatry in the Field of Women’s Health, Harvard Medical School

Benjamin Kann, MD

Assistant Professor, Brigham and Women’s Hospital & Harvard Medical School

Tatsuo Kawai, MD, PhD

Director of the Legorreta Center for Clinical Transplantation Tolerance, A.Benedict Cosimi Chair in Transplant Surgery, Massachusetts General Hospital; Professor of Surgery, Harvard Medical School

Albert Kim, MD

Assistant Physician, Mass General Cancer Center; Assistant Professor, Harvard Medical School

Roger Kitterman

Senior Vice President, Ventures and Business Development & Licensing, Mass General Brigham Managing Partner, Mass General Brigham Ventures

Lotte Bjerre Knudsen, DMSc

Chief Scientific Advisor, Novo Nordisk

Vesela Kovacheva, MD, PhD

Director of Translational and Clinical Research, Mass General Brigham; Assistant Professor of Anesthesia, Harvard Medical School

Jonathan Kraft

President, The Kraft Group; Board Chair, Massachusetts General Hospital

John Krystal, MD

Chair, Department of Psychiatry, Yale School of Medicine

Daniel Kuritzkes, MD

Chief, Division of Infectious Diseases, Brigham and Women’s Hospital; Harriet Ryan Albee Professor of Medicine, Harvard Medical School

Bruce Levy, MD

Physician-In-Chief and Co-Chair, Department of Medicine, Brigham and Women’s Hospital; Parker B. Francis Professor of Medicine, Harvard Medical School

Katherine Liao, MD

Associate Physician, Department of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital; Associate Professor of Medicine and Biomedical Informatics, Harvard Medical School

David Louis, MD

Enterprise Chief, Pathology, Mass General Brigham Benjamin Castleman Professor of Pathology, Harvard Medical School

Tim Luker, PhD

VP, Ventures & West Coast Head, Eli Lilly

Andrew Luster, MD, PhD

Chief, Division of Rheumatology, Allergy and Immunology; Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Persis, Cyrus and Marlow B. Harrison Professor of Medicine, Harvard Medical School

Allen Lutz

Health Care Services Analyst, BofA Global Research

Calum MacRae MD, PhD

Vice Chair for Scientific Innovation, Department of Medicine, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Joren Madsen, MD, PhD

Director, MGH Transplant Center; Paul S. Russell/Warner-Lambert Professor of Surgery, Harvard Medical School

Faisal Mahmood, PhD

Associate Professor, Brigham and Women’s Hospital & Harvard Medical School

Peter Marks, MD, PhD

Director, Center for Biologics Evaluation and Research, FDA

Marcela Maus, MD, PhD

Director of Cellular Therapy and Paula O’Keeffe Chair in Cancer Research, Krantz Family Center for Cancer Research and Mass General Cancer Center; Associate Director, Gene and Cell Therapy Institute, Mass General Brigham; Associate Professor, Harvard Medical School

Thorsten Mempel, MD, PhD

Associate Director, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital; Professor of Medicine, Harvard Medical School

Rebecca Mishuris, MD

Chief Medical Information Officer, Mass General Brigham; Member of the Faculty, Harvard Medical School

Pradeep Natarajan, MD

Director of Preventive Cardiology, Paul & Phyllis Fireman Endowed Chair in Vascular Medicine, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Nawal Nour, MD

Chair, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital; Associate Professor, Kate Macy Ladd Professorship, Harvard Medical School

Heather O’Sullivan, MS, RN, AGNP

President, Mass General Brigham Healthcare at Home

Anne Oxrider

Senior Vice President, Benefits Executive, Bank of America

Claire-Cecile Pierre, MD

Vice President, Community Health Programs, Mass General Brigham; Instructor in Medicine, Harvard Medical School

Richard Pierson III, MD

Scientific Director, Center for Transplantation Sciences, Massachusetts General Hospital; Professor of Surgery, Harvard Medical School

Mark Poznansky, MD, PhD

Director, Vaccine and Immunotherapy Center, Massachusetts General Hospital; Steve and Deborah Gorlin MGH Research Scholar; Professor of Medicine, Harvard Medical School

Yakeel Quiroz, PhD

Director, Familial Dementia Neuroimaging Lab and Director, Multicultural Alzheimer’s Prevention Program, Massachusetts General Hospital; Paul B. and Sandra M. Edgerley MGH Research Scholar; Associate Professor, Harvard Medical School

Heidi Rehm, PhD

Chief Genomics Officer, Massachusetts General Hospital; Professor of Pathology, Harvard Medical School

Leonardo Riella, MD, PhD

Medical Director of Kidney Transplantation, Massachusetts General Hospital; Harold and Ellen Danser Endowed Chair in Transplantation, Harvard Medical School

Jorge Rodriguez, MD

Clinician-investigator, Brigham and Women’s Hospital; Assistant Professor, Harvard Medical School

Adam Ron

Health Care Facilities and Managed Care Analyst, BofA Global Research

David Ryan, MD

Physician-in-Chief, Mass General Brigham Cancer; Professor of Medicine, Harvard Medical School

Michael Ryskin

Life Science Tools & Diagnostics Analyst, BofA Global Research

Alkesh Shah

Head of US Equity Software Research, BofA Global Research

Angela Shen, MD

Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation

Gregory Simon

President, Simonovation

Prabhjot Singh, MD, PhD

Senior Advisor, Strategic Initiatives Peterson Health Technology Institute

Brendan Singleton

Healthcare Equity Capital Markets, BofA Securities

Caroline Sokol, MD, PhD

Assistant Physician, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Daniel Solomon, MD

Matthew H. Liang Distinguished Chair in Arthritis and Population Health, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Scott Solomon, MD

Director, Clinical Trials Outcomes Center; Edward D. Frohlich Distinguished Chair in Cardiovascular Pathophysiology, Brigham and Women’s Hospital; Professor of Medicine, Harvard Medical School

Fatima Cody Stanford, MD

Obesity Medicine Physician Scientist, Massachusetts General Hospital; Associate Professor of Medicine and Pediatrics, Harvard Medical School

Shannon Stott, PhD

Associate Investigator, Krantz Family Center for Cancer Research and Mass General Cancer Center; d’Arbeloff Research Scholar, Massachusetts General Hospital; Associate Investigator, Krantz Family Center for Cancer Research Harvard Medical School

Alec Stranahan, PhD

SMid-Cap Biotech Analyst, BofA Global Research

Marc Succi, MD

Executive Director, Mass General Brigham MESH Incubator; Associate Chair of Innovation & Commercialization, Mass General Brigham Radiology; Assistant Professor, Harvard Medical School

Guillermo Tearney, MD, PhD

Principal Investigator, Wellman Center for Photomedicine, Massachusetts General Hospital; Remondi Family Endowed MGH Research Institute Chair; Professor of Pathology, Harvard Medical School

David Ting, MD

Associate Clinical Director for Innovation, Mass General Cancer Center; Associate Professor of Medicine, Harvard Medical School

Raul Uppot, MD

Interventional Radiologist, Massachusetts General Hospital; Associate Professor, Harvard Medical School

Chris Varma, PhD

Co-founder, Chairman & CEO, Frontier Medicines

Kaveeta Vasisht, MD, PharmD

Associate Commissioner, Women’s Health, U.S. Food and Drug Administration

Alexandra-Chloé Villani PhD

Investigator, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Kate Walsh

Secretary of Health and Human Services, State of Massachusetts

David Walt, PhD

Professor of Pathology, Brigham and Women’s Hospital; Hansjörg Wyss Professor of Biologically Inspired Engineering, Harvard Medical School

Jennifer Warner-Schmidt, PhD

Vice President, Scientific Affairs, Transcend Therapeutics

Renee Wegrzyn, PhD

Director, Advanced Research Projects Agency for Health

Christoph Westphal, MD, PhD

General Partner, Longwood Fund

Deborah Wexler, MD

Chief, Diabetes Unit, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School

Charlie Yang, PhD

Large/SMid-Cap Biotech and Major Pharma Analyst, BofA Global Research

Nathan Yozwiak, PhD

Head of Research, Gene and Cell Therapy Institute, Mass General Brigham

Jason Zemansky, PhD

SMid-Cap Biotech Analyst, BofA Global Research

Alice Zheng, MD

Principal, RH Capital

We continue to confirm more speakers. Please check back regularly for updates.